Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Aug;85(3):446–452. doi: 10.1054/bjoc.2001.1921

The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition

S D Webley 1, S J Welsh 1, A L Jackman 1, G W Aherne 1
PMCID: PMC2364072  PMID: 11487279

Abstract

Thymidylate synthase (TS) is an important enzyme catalysing the reductive methylation of dUMP to dTMP that is further metabolized to dTTP for DNA synthesis. Loss of viability following TS inhibition occurs as a consequence of depleted dTTP pools and at least in some cell lines, accumulation of dUTP and subsequent misincorporation of uracil into DNA. The expansion in dUTP pools is largely determined by the expression of the pyrophosphatase, dUTPase. Our previous work has shown that following TS inhibition the ability to accumulate dUTP was associated with an earlier growth inhibitory effect. 3 human lung tumour cell lines and HT29 human colon tumour cells transfected with dUTPase have been used to investigate the relationship between loss of viability following TS inhibition and dUTP accumulation. Cell cycle arrest typical of TS inhibition was an early event in all cell lines and occurred irrespective of the ability to accumulate dUTP or p53 function. However, a large expansion of dUTP pools was associated with mature DNA damage (4 h) and an earlier loss of viability following TS inhibition compared to cells in which dUTP pools were not expanded. In A549 cells damage to mature DNA may have been exacerbated by significantly higher activity of the excision repair enzyme, uracil-DNA glycosylase. Consistent with results using different inhibitors of TS, transfection of dUTPase into HT29 cells significantly reduced the cytotoxicity of a 24 h but not 48 h exposure to ZD9331. Although loss of viability can be mediated through dTTP deprivation alone, the uracil misincorporation pathway resulted in an earlier commitment to cell death. The relevance of this latter pathway in the clinical response to TS inhibitors deserves further investigation. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: dUTPase, thymidylate synthase, ZD9331, dUTP, uracil misincorporation

Full Text

The Full Text of this article is available as a PDF (155.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aherne G. W., Hardcastle A., Raynaud F., Jackman A. L. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol. 1996 May 17;51(10):1293–1301. doi: 10.1016/0006-2952(96)00035-4. [DOI] [PubMed] [Google Scholar]
  2. Brynolf K., Eliasson R., Reichard P. Formation of Okazaki fragments in polyoma DNA synthesis caused by misincorporation of uracil. Cell. 1978 Mar;13(3):573–580. doi: 10.1016/0092-8674(78)90330-6. [DOI] [PubMed] [Google Scholar]
  3. Canman C. E., Radany E. H., Parsels L. A., Davis M. A., Lawrence T. S., Maybaum J. Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichia coli deoxyuridinetriphosphatase. Cancer Res. 1994 May 1;54(9):2296–2298. [PubMed] [Google Scholar]
  4. Caradonna S. J., Cheng Y. C. Uracil DNA-glycosylase. Purification and properties of this enzyme isolated from blast cells of acute myelocytic leukemia patients. J Biol Chem. 1980 Mar 25;255(6):2293–2300. [PubMed] [Google Scholar]
  5. Chong L. K., Tattersall M. H. 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase. Biochem Pharmacol. 1995 Mar 15;49(6):819–827. doi: 10.1016/0006-2952(94)00458-x. [DOI] [PubMed] [Google Scholar]
  6. Curtin N. J., Harris A. L., Aherne G. W. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 1991 May 1;51(9):2346–2352. [PubMed] [Google Scholar]
  7. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M. A., Lassota P., Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13(8):795–808. doi: 10.1002/cyto.990130802. [DOI] [PubMed] [Google Scholar]
  8. Fisher T. C., Milner A. E., Gregory C. D., Jackman A. L., Aherne G. W., Hartley J. A., Dive C., Hickman J. A. bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res. 1993 Jul 15;53(14):3321–3326. [PubMed] [Google Scholar]
  9. Goulian M., Bleile B. M., Dickey L. M., Grafstrom R. H., Ingraham H. A., Neynaber S. A., Peterson M. S., Tseng B. Y. Mechanism of thymineless death. Adv Exp Med Biol. 1986;195(Pt B):89–95. doi: 10.1007/978-1-4684-1248-2_15. [DOI] [PubMed] [Google Scholar]
  10. Hartwell L. H., Kastan M. B. Cell cycle control and cancer. Science. 1994 Dec 16;266(5192):1821–1828. doi: 10.1126/science.7997877. [DOI] [PubMed] [Google Scholar]
  11. Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Niimi T., Shimokata K., Yamakawa K., Nakamura Y., Ueda R. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993 Jan 1;53(1):1–4. [PubMed] [Google Scholar]
  12. Houghton J. A., Harwood F. G., Houghton P. J. Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res. 1994 Sep 15;54(18):4967–4973. [PubMed] [Google Scholar]
  13. Houghton J. A., Tillman D. M., Harwood F. G. Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res. 1995 Jul;1(7):723–730. [PubMed] [Google Scholar]
  14. Jackman A. L., Kimbell R., Aherne G. W., Brunton L., Jansen G., Stephens T. C., Smith M. N., Wardleworth J. M., Boyle F. T. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res. 1997 Jun;3(6):911–921. [PubMed] [Google Scholar]
  15. Jackson R. C., Jackman A. L., Calvert A. H. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells. Biochem Pharmacol. 1983 Dec 15;32(24):3783–3790. doi: 10.1016/0006-2952(83)90150-8. [DOI] [PubMed] [Google Scholar]
  16. Kohn K. W. Principles and practice of DNA filter elution. Pharmacol Ther. 1991;49(1-2):55–77. doi: 10.1016/0163-7258(91)90022-e. [DOI] [PubMed] [Google Scholar]
  17. Matsui S. I., Arredondo M. A., Wrzosek C., Rustum Y. M. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res. 1996 Oct 15;56(20):4715–4723. [PubMed] [Google Scholar]
  18. Muller-Weeks S. J., Caradonna S. Specific association of cyclin-like uracil-DNA glycosylase with the proliferating cell nuclear antigen. Exp Cell Res. 1996 Aug 1;226(2):346–355. doi: 10.1006/excr.1996.0235. [DOI] [PubMed] [Google Scholar]
  19. Nelson W. G., Kastan M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol. 1994 Mar;14(3):1815–1823. doi: 10.1128/mcb.14.3.1815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. O'Connor P. M. Mammalian G1 and G2 phase checkpoints. Cancer Surv. 1997;29:151–182. [PubMed] [Google Scholar]
  21. Parsels L. A., Parsels J. D., Wagner L. M., Loney T. L., Radany E. H., Maybaum J. Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells. Cancer Chemother Pharmacol. 1998;42(5):357–362. doi: 10.1007/s002800050829. [DOI] [PubMed] [Google Scholar]
  22. Savage J. R., Prasad R. Generalized blocking in S phase by methotrexate. Mutat Res. 1988 Sep;201(1):195–201. doi: 10.1016/0027-5107(88)90126-1. [DOI] [PubMed] [Google Scholar]
  23. Skelton L. A., Ormerod M. G., Titley J. C., Jackman A. L. Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Cytometry. 1998 Sep 1;33(1):56–66. doi: 10.1002/(sici)1097-0320(19980901)33:1<56::aid-cyto7>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  24. Tang H. Y., Weber K. L., Lawrence T. S., Merchant A. K., Maybaum J. Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells. Cancer Chemother Pharmacol. 1996;37(5):486–490. doi: 10.1007/s002800050416. [DOI] [PubMed] [Google Scholar]
  25. Taylor I. W., Slowiaczek P., Francis P. R., Tattersall M. H. Purine modulation of methotrexate cytotoxicity in mammalian cell lines. Cancer Res. 1982 Dec;42(12):5159–5164. [PubMed] [Google Scholar]
  26. Tonkinson J. L., Marder P., Andis S. L., Schultz R. M., Gossett L. S., Shih C., Mendelsohn L. G. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol. 1997;39(6):521–531. doi: 10.1007/s002800050608. [DOI] [PubMed] [Google Scholar]
  27. Webley S. D., Hardcastle A., Ladner R. D., Jackman A. L., Aherne G. W. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331. Br J Cancer. 2000 Sep;83(6):792–799. doi: 10.1054/bjoc.2000.1358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yin M. B., Guimaraes M. A., Zhang Z. G., Arredondo M. A., Rustum Y. M. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Cancer Res. 1992 Nov 1;52(21):5900–5905. [PubMed] [Google Scholar]
  29. Zambetti G. P., Levine A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 1993 Jul;7(10):855–865. doi: 10.1096/fasebj.7.10.8344485. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES